547 related articles for article (PubMed ID: 24135210)
1. Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications.
Pertwee RG
Proc Nutr Soc; 2014 Feb; 73(1):96-105. PubMed ID: 24135210
[TBL] [Abstract][Full Text] [Related]
2. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment.
Guindon J; Lai Y; Takacs SM; Bradshaw HB; Hohmann AG
Pharmacol Res; 2013 Jan; 67(1):94-109. PubMed ID: 23127915
[TBL] [Abstract][Full Text] [Related]
3. Chemical probes of endocannabinoid metabolism.
Blankman JL; Cravatt BF
Pharmacol Rev; 2013 Apr; 65(2):849-71. PubMed ID: 23512546
[TBL] [Abstract][Full Text] [Related]
4. Endocannabinoid contribution to Δ9-tetrahydrocannabinol discrimination in rodents.
Wiley JL; Walentiny DM; Wright MJ; Beardsley PM; Burston JJ; Poklis JL; Lichtman AH; Vann RE
Eur J Pharmacol; 2014 Aug; 737():97-105. PubMed ID: 24858366
[TBL] [Abstract][Full Text] [Related]
5. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors.
Moreira FA; Kaiser N; Monory K; Lutz B
Neuropharmacology; 2008 Jan; 54(1):141-50. PubMed ID: 17709120
[TBL] [Abstract][Full Text] [Related]
6. Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors.
Pryce G; Cabranes A; Fernández-Ruiz J; Bisogno T; Di Marzo V; Long JZ; Cravatt BF; Giovannoni G; Baker D
Mult Scler; 2013 Dec; 19(14):1896-904. PubMed ID: 23625705
[TBL] [Abstract][Full Text] [Related]
7. Effects of fatty acid amide hydrolase (FAAH) inhibitors on working memory in rats.
Panlilio LV; Thorndike EB; Nikas SP; Alapafuja SO; Bandiera T; Cravatt BF; Makriyannis A; Piomelli D; Goldberg SR; Justinova Z
Psychopharmacology (Berl); 2016 May; 233(10):1879-88. PubMed ID: 26558620
[TBL] [Abstract][Full Text] [Related]
8. Guineensine is a novel inhibitor of endocannabinoid uptake showing cannabimimetic behavioral effects in BALB/c mice.
Nicolussi S; Viveros-Paredes JM; Gachet MS; Rau M; Flores-Soto ME; Blunder M; Gertsch J
Pharmacol Res; 2014 Feb; 80():52-65. PubMed ID: 24412246
[TBL] [Abstract][Full Text] [Related]
9. The effects of fatty acid amide hydrolase and monoacylglycerol lipase inhibitor treatments on lipopolysaccharide-induced airway inflammation in mice.
Abohalaka R; Bozkurt TE; Nemutlu E; Onder SC; Sahin-Erdemli I
Pulm Pharmacol Ther; 2020 Jun; 62():101920. PubMed ID: 32416152
[TBL] [Abstract][Full Text] [Related]
10. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo.
Long JZ; Nomura DK; Vann RE; Walentiny DM; Booker L; Jin X; Burston JJ; Sim-Selley LJ; Lichtman AH; Wiley JL; Cravatt BF
Proc Natl Acad Sci U S A; 2009 Dec; 106(48):20270-5. PubMed ID: 19918051
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: evidence that VDM11 acts as an FAAH substrate.
Vandevoorde S; Fowler CJ
Br J Pharmacol; 2005 Aug; 145(7):885-93. PubMed ID: 15895107
[TBL] [Abstract][Full Text] [Related]
12. Endocannabinoid regulation of homeostatic feeding and stress-induced alterations in food intake in male rats.
Sticht MA; Lau DJ; Keenan CM; Cavin JB; Morena M; Vemuri VK; Makriyannis A; Cravatt BF; Sharkey KA; Hill MN
Br J Pharmacol; 2019 May; 176(10):1524-1540. PubMed ID: 30051485
[TBL] [Abstract][Full Text] [Related]
13. Cannabinoid CB
Leonard MZ; Alapafuja SO; Ji L; Shukla VG; Liu Y; Nikas SP; Makriyannis A; Bergman J; Kangas BD
J Pharmacol Exp Ther; 2017 Dec; 363(3):314-323. PubMed ID: 28947487
[TBL] [Abstract][Full Text] [Related]
14. Discovery and development of endocannabinoid-hydrolyzing enzyme inhibitors.
Minkkilä A; Saario S; Nevalainen T
Curr Top Med Chem; 2010; 10(8):828-58. PubMed ID: 20370710
[TBL] [Abstract][Full Text] [Related]
15. Fatty pain cures.
Imming P
Chem Biol; 2007 Dec; 14(12):1311-2. PubMed ID: 18096498
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.
Walentiny DM; Vann RE; Wiley JL
Neuropharmacology; 2015 Jun; 93():237-42. PubMed ID: 25698527
[TBL] [Abstract][Full Text] [Related]
17. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels.
Petrosino S; Di Marzo V
Curr Opin Investig Drugs; 2010 Jan; 11(1):51-62. PubMed ID: 20047159
[TBL] [Abstract][Full Text] [Related]
18. The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice.
Wilkerson JL; Ghosh S; Mustafa M; Abdullah RA; Niphakis MJ; Cabrera R; Maldonado RL; Cravatt BF; Lichtman AH
Neuropharmacology; 2017 Mar; 114():156-167. PubMed ID: 27890602
[TBL] [Abstract][Full Text] [Related]
19. Attenuation of anticipatory nausea in a rat model of contextually elicited conditioned gaping by enhancement of the endocannabinoid system.
Limebeer CL; Abdullah RA; Rock EM; Imhof E; Wang K; Lichtman AH; Parker LA
Psychopharmacology (Berl); 2014 Feb; 231(3):603-12. PubMed ID: 24043345
[TBL] [Abstract][Full Text] [Related]
20. Stimulation of diuresis and natriuresis by renomedullary infusion of a dual inhibitor of fatty acid amide hydrolase and monoacylglycerol lipase.
Ahmad A; Daneva Z; Li G; Dempsey SK; Li N; Poklis JL; Lichtman A; Li PL; Ritter JK
Am J Physiol Renal Physiol; 2017 Nov; 313(5):F1068-F1076. PubMed ID: 28768662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]